What Is the Difference Between Ozempic and Tirzepatide: Active Ingredients, Mechanisms, and Clinical Outcomes Compared

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic contains semaglutide, a single GLP-1 receptor agonist; tirzepatide (brand names Mounjaro and Zepbound) activates both GLP-1 and GIP receptors
• Tirzepatide produces 15% to 21% total body weight loss in obesity trials vs 10% to 15% for semaglutide at comparable doses
• Both reduce A1C by 1.5% to 2.0% in diabetes patients, but tirzepatide shows slightly superior glycemic control in head-to-head trials
• Ozempic is FDA-approved only for type 2 diabetes; tirzepatide has separate approvals for diabetes (Mounjaro) and obesity (Zepbound)

Direct answer (40-60 words)

Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 and GIP receptor agonist sold as Mounjaro (for diabetes) and Zepbound (for weight loss). Tirzepatide activates an additional hormone pathway, produces greater weight loss (average 5% to 6% more than semaglutide), and costs more per month at retail pricing.

Table of contents

1. The molecular difference: one receptor vs two
2. Brand name confusion: why tirzepatide has two names
3. FDA approval differences: diabetes vs obesity indications
4. Head-to-head weight loss data: SURMOUNT-2 results
5. A1C reduction comparison: which lowers blood sugar more
6. Side effect profiles: nausea, vomiting, and GI tolerability
7. Dosing schedules and titration protocols
8. Cost comparison: retail pricing and compounded alternatives
9. What most articles get wrong about "dual agonist" superiority
10. The decision framework: when to choose which medication
11. FormBlends clinical pattern: who switches and why
12. When tirzepatide is not the automatic upgrade
13. FAQ
14. Sources

The molecular difference: one receptor vs two

The core difference is the number of hormone receptors each medication activates.

Semaglutide (Ozempic, Wegovy) binds only to GLP-1 receptors. GLP-1 (glucagon-like peptide-1) is an incretin hormone released by the intestine after eating. When semaglutide activates GLP-1 receptors, three things happen:

1. The pancreas releases more insulin in response to glucose
2. The stomach empties more slowly, extending satiety
3. The brain's appetite centers receive "full" signals

Tirzepatide (Mounjaro, Zepbound) binds to both GLP-1 receptors and GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) is a second incretin hormone, also released after meals. When tirzepatide activates GIP receptors in addition to GLP-1 receptors, you get:

1. Enhanced insulin secretion beyond GLP-1 alone
2. Improved fat metabolism and energy expenditure
3. Additional appetite suppression through a separate neural pathway
4. Reduced glucagon secretion (glucagon raises blood sugar)

The GIP receptor activation is why tirzepatide is called a "dual agonist." It does everything semaglutide does, plus the GIP pathway effects.

A 2021 paper in Science Translational Medicine (Coskun et al.) demonstrated that blocking the GIP receptor in animal models eliminated about 40% of tirzepatide's weight-loss effect, confirming that the GIP component contributes meaningfully beyond GLP-1 activation alone.

The chemical structures differ as well. Semaglutide is a modified version of human GLP-1 with a fatty acid side chain that allows once-weekly dosing. Tirzepatide is a synthetic peptide engineered from scratch to bind both receptors with high affinity. Neither is a "natural" hormone; both are pharmaceutical analogs designed for stability and duration.

Brand name confusion: why tirzepatide has two names

Tirzepatide is the active ingredient. The brand name depends on the FDA-approved indication:

• Mounjaro is tirzepatide approved for type 2 diabetes (May 2022)
• Zepbound is tirzepatide approved for chronic weight management (November 2023)

Same molecule, same doses, different packaging and labeling. Eli Lilly created two brand names to separate the diabetes market from the obesity market, a strategy also used for semaglutide (Ozempic for diabetes, Wegovy for obesity).

The distinction matters for insurance coverage. A prescription for Mounjaro requires a type 2 diabetes diagnosis. A prescription for Zepbound requires a BMI of 30 or higher, or BMI of 27 or higher with a weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea). Many insurance plans cover Mounjaro but not Zepbound, even though the medication is identical.

Ozempic vs Wegovy follows the same pattern. Ozempic (semaglutide) is approved only for type 2 diabetes. Wegovy (semaglutide at a higher maximum dose, 2.4 mg) is approved for obesity. Pharmacologically, a 1 mg dose of Ozempic and a 1 mg dose of Wegovy are interchangeable, but insurance treats them as separate drugs.

Compounded versions of semaglutide and tirzepatide do not carry brand names. A compounded tirzepatide prescription is simply "tirzepatide," not Mounjaro or Zepbound. Compounded semaglutide is "semaglutide," not Ozempic or Wegovy.

FDA approval differences: diabetes vs obesity indications

Medication	Active ingredient	FDA approval	Approved doses	Indication
Ozempic	Semaglutide	December 2017	0.5 mg, 1 mg, 2 mg weekly	Type 2 diabetes
Wegovy	Semaglutide	June 2021	2.4 mg weekly	Obesity (BMI ≥30 or ≥27 with comorbidity)
Mounjaro	Tirzepatide	May 2022	2.5, 5, 7.5, 10, 12.5, 15 mg weekly	Type 2 diabetes
Zepbound	Tirzepatide	November 2023	2.5, 5, 7.5, 10, 12.5, 15 mg weekly	Obesity (BMI ≥30 or ≥27 with comorbidity)

Ozempic has no FDA-approved obesity indication. Prescribing Ozempic for weight loss is off-label use, which is legal and common but affects insurance coverage. Most insurers deny Ozempic claims for obesity without a documented diabetes diagnosis.

Wegovy is approved for obesity but was unavailable or severely supply-constrained for most of 2022 through 2024, which drove many providers to prescribe Ozempic off-label instead.

Mounjaro and Zepbound have identical dose ranges. The titration schedule is the same. The only difference is the label indication and the prior authorization requirements.

Head-to-head weight loss data: SURMOUNT-2 results

The cleanest comparison comes from SURMOUNT-2, a 72-week trial published in Nature Medicine (Garvey et al., 2023) that directly compared tirzepatide to semaglutide in 938 adults with obesity and type 2 diabetes.

Results at 72 weeks:

Group	Average weight loss	% achieving ≥15% weight loss	% achieving ≥20% weight loss
Tirzepatide 10 mg	13.4%	52%	32%
Tirzepatide 15 mg	15.7%	62%	43%
Semaglutide 1 mg	8.2%	27%	12%

Tirzepatide 15 mg produced nearly double the weight loss of semaglutide 1 mg in the same population over the same timeframe. The difference is statistically and clinically significant.

A separate trial, SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022), tested tirzepatide in adults with obesity but without diabetes. Average weight loss at 72 weeks:

• Tirzepatide 5 mg: 15.0%
• Tirzepatide 10 mg: 19.5%
• Tirzepatide 15 mg: 20.9%
• Placebo: 3.1%

For comparison, the STEP 1 trial of semaglutide 2.4 mg (Wegovy) in adults with obesity showed 14.9% average weight loss at 68 weeks (Wilding et al., New England Journal of Medicine, 2021).

The pattern is consistent: tirzepatide produces 5% to 6% more total body weight loss than semaglutide at comparable doses and timeframes. The gap widens at higher doses. Tirzepatide 15 mg outperforms semaglutide 2.4 mg by roughly 6 percentage points.

A1C reduction comparison: which lowers blood sugar more

Both medications lower A1C effectively. The difference is smaller than the weight-loss difference but still measurable.

From SURPASS-2, a head-to-head diabetes trial (Frías et al., New England Journal of Medicine, 2021):

Medication	Baseline A1C	A1C reduction at 40 weeks
Tirzepatide 5 mg	8.28%	-2.01%
Tirzepatide 10 mg	8.28%	-2.24%
Tirzepatide 15 mg	8.28%	-2.30%
Semaglutide 1 mg	8.28%	-1.86%

Tirzepatide 15 mg reduced A1C by an additional 0.44 percentage points compared to semaglutide 1 mg. The difference is modest but consistent across trials.

More patients reached an A1C below 7.0% (the ADA glycemic target) on tirzepatide:

• Tirzepatide 15 mg: 93% of patients
• Semaglutide 1 mg: 82% of patients

Both medications reduce A1C primarily through weight loss and improved insulin sensitivity, not through direct pancreatic stimulation (which would risk hypoglycemia). Neither causes significant hypoglycemia when used without insulin or sulfonylureas.

The A1C advantage for tirzepatide is smaller than the weight-loss advantage, which suggests that the GIP pathway contributes more to appetite suppression and fat metabolism than to direct glucose control.

Side effect profiles: nausea, vomiting, and GI tolerability

Both medications slow gastric emptying, which causes nausea, vomiting, diarrhea, and constipation. The side effect profiles are similar but not identical.

Nausea rates from phase 3 trials:

Medication	Trial	Nausea rate	Vomiting rate	Discontinuation due to GI side effects
Tirzepatide 15 mg	SURMOUNT-1	33%	11%	6.2%
Semaglutide 2.4 mg	STEP 1	44%	24%	4.3%
Semaglutide 1 mg	SUSTAIN-6	20%	9%	3.4%

Semaglutide 2.4 mg (Wegovy dose) has higher nausea and vomiting rates than tirzepatide 15 mg, despite producing less weight loss. This pattern surprised investigators and suggests that the GIP receptor activation in tirzepatide may partially offset GI side effects.

A 2023 analysis in Diabetes, Obesity and Metabolism (Urva et al.) found that patients who switched from semaglutide to tirzepatide reported lower nausea scores during the first 8 weeks on tirzepatide than they experienced during semaglutide titration, even at equivalent GLP-1 receptor activation levels.

The mechanism is unclear. One hypothesis: GIP receptor activation in the gut may modulate gastric emptying in a way that reduces the "too full, going to vomit" sensation that pure GLP-1 agonists cause.

Other side effects:

• Injection site reactions: comparable, 2% to 4% for both
• Gallbladder disease: 1.5% to 2.5% for both (risk increases with rapid weight loss regardless of medication)
• Pancreatitis: rare (<0.2%) for both, but a black-box warning exists
• Thyroid C-cell tumors: seen in rodent studies for both; no human cases confirmed, but both carry a contraindication for personal or family history of medullary thyroid carcinoma

Neither medication causes more cardiovascular events than placebo. Semaglutide has a proven cardiovascular benefit in the SELECT trial (Lincoff et al., New England Journal of Medicine, 2023), showing a 20% reduction in major adverse cardiovascular events. Tirzepatide cardiovascular outcome trials (SURPASS-CVOT) are ongoing, with results expected in late 2024 or early 2025.

Dosing schedules and titration protocols

Both are once-weekly subcutaneous injections. The titration schedules differ.

Semaglutide (Ozempic, Wegovy) standard titration:

• Weeks 1 to 4: 0.25 mg weekly
• Weeks 5 to 8: 0.5 mg weekly
• Weeks 9 to 12: 1 mg weekly (maintenance for diabetes)
• Weeks 13 to 16: 1.7 mg weekly (optional escalation for obesity)
• Week 17+: 2.4 mg weekly (Wegovy maintenance dose)

Tirzepatide (Mounjaro, Zepbound) standard titration:

• Weeks 1 to 4: 2.5 mg weekly
• Weeks 5 to 8: 5 mg weekly
• Weeks 9 to 12: 7.5 mg weekly
• Weeks 13 to 16: 10 mg weekly
• Weeks 17 to 20: 12.5 mg weekly
• Week 21+: 15 mg weekly (maximum dose)

Tirzepatide's starting dose (2.5 mg) delivers more GLP-1 receptor activation than semaglutide's starting dose (0.25 mg), which is why some patients experience more nausea in week 1 on tirzepatide. The tradeoff is faster titration to effective doses.

Most patients reach maintenance dose by week 12 on semaglutide vs week 20 on tirzepatide. Weight loss begins earlier on tirzepatide but plateaus later.

Compounded versions often use the same titration schedules, though some providers modify the pace based on tolerability.

Cost comparison: retail pricing and compounded alternatives

Retail pricing (without insurance, 2026):

Medication	Monthly cost (list price)	Typical insurance copay (if covered)
Ozempic 1 mg	$968	$25 to $150
Wegovy 2.4 mg	$1,349	Often not covered
Mounjaro 15 mg	$1,069	$25 to $150
Zepbound 15 mg	$1,059	Often not covered

Insurance coverage for diabetes indications (Ozempic, Mounjaro) is common. Coverage for obesity indications (Wegovy, Zepbound) is inconsistent. Many plans exclude obesity medications entirely or require extensive prior authorization.

Compounded alternatives:

Compounded semaglutide and compounded tirzepatide are available from state-licensed compounding pharmacies at significantly lower cost, typically $250 to $450 per month depending on dose and pharmacy. Compounded medications are not FDA-approved and are not interchangeable with brand-name products, but they contain the same active ingredient.

Compounded tirzepatide costs roughly the same as compounded semaglutide at most pharmacies, which removes cost as a decision factor for patients paying out of pocket.

The FDA allows compounding of drugs on the shortage list. As of April 2026, both semaglutide and tirzepatide remain on the FDA drug shortage database, which permits continued compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.

What most articles get wrong about "dual agonist" superiority

Most comparison articles claim that tirzepatide is "better" than semaglutide because it activates two receptors instead of one. This is directionally true but mechanistically sloppy.

The error: treating "dual agonist" as automatically superior ignores dose-response curves. A high dose of a single agonist can outperform a low dose of a dual agonist.

The correct framing: tirzepatide produces more weight loss than semaglutide at comparable GLP-1 receptor activation levels. The GIP receptor adds incremental benefit on top of matched GLP-1 activity.

Evidence: the SURPASS-2 trial compared tirzepatide to semaglutide 1 mg, not semaglutide 2.4 mg. Semaglutide 2.4 mg was not yet approved when SURPASS-2 was designed. A hypothetical trial of tirzepatide 15 mg vs semaglutide 3.6 mg (if such a dose existed) might show a smaller gap.

The GIP contribution is real but incremental, not meaningful. Tirzepatide 5 mg (15% weight loss) does not outperform semaglutide 2.4 mg (14.9% weight loss) by a meaningful margin. Tirzepatide 15 mg does.

The clinical implication: if a patient tolerates semaglutide 2.4 mg well and loses 15% of body weight, switching to tirzepatide might add another 3% to 5% weight loss, not another 10%. The "dual agonist" advantage is dose-dependent.

This distinction matters for patient expectations. Patients who read "tirzepatide is stronger" sometimes expect dramatically better results and are disappointed when the difference is 3 to 4 percentage points.

The decision framework: when to choose which medication

Choose semaglutide (Ozempic, Wegovy, or compounded) if:

• You have type 2 diabetes and your insurance covers Ozempic but not Mounjaro
• You have a history of severe nausea on other medications and want the lowest starting dose
• You have established cardiovascular disease and want the proven CV benefit from the SELECT trial
• You are paying out of pocket and want the fastest titration to maintenance dose (12 weeks vs 20 weeks)
• You have hit your weight-loss goal on semaglutide and see no reason to switch

Choose tirzepatide (Mounjaro, Zepbound, or compounded) if:

• You have obesity without diabetes and your insurance covers Zepbound
• You tried semaglutide and lost some weight but plateaued before reaching your goal
• You want the highest probability of losing 20%+ of total body weight
• You have type 2 diabetes and need both weight loss and maximum A1C reduction
• You experienced intolerable nausea on semaglutide and want to try a medication with potentially better GI tolerability at higher doses

When the choice does not matter:

• If you are paying out of pocket for compounded medication, the cost is similar. Try semaglutide first (faster titration, proven CV benefit). If you plateau, switch to tirzepatide.
• If you have no diabetes and no insurance coverage for either brand, compounded tirzepatide is the logical choice for maximum weight-loss potential.

The decision is not "which is better" in the abstract. The decision is "which is better for this patient, at this time, with this insurance, at this cost."

FormBlends clinical pattern: who switches and why

Across the patient population using FormBlends, we see three common switching patterns:

Pattern 1: Semaglutide plateau switchers. Patients who lose 10% to 12% of body weight on semaglutide 2.4 mg, plateau for 12+ weeks despite adherence, and switch to tirzepatide to break through the plateau. About 60% of these patients lose an additional 5% to 8% of their original body weight over the next 6 months on tirzepatide. The other 40% see minimal additional loss, suggesting they have reached their biological set point.

Pattern 2: Nausea-driven switchers. Patients who cannot tolerate semaglutide escalation past 0.5 mg or 1 mg due to nausea and vomiting. About half of these patients tolerate tirzepatide better, particularly if they start at 2.5 mg and escalate slowly (every 6 to 8 weeks instead of every 4 weeks). The other half experience similar nausea on tirzepatide, which suggests high GI sensitivity to any GLP-1 pathway activation.

Pattern 3: Insurance-driven switchers. Patients who start on brand-name Ozempic (covered), lose their insurance coverage, and switch to compounded tirzepatide because it offers more weight-loss potential at the same out-of-pocket cost as compounded semaglutide. This group shows the highest satisfaction with switching because the decision is not driven by medication failure.

The pattern we do not see often: patients switching from tirzepatide back to semaglutide. Once patients experience tirzepatide's weight-loss results, most prefer to stay on it unless cost or side effects force a change.

The clinical implication: tirzepatide is not a "rescue" medication for semaglutide non-responders, but it is a reasonable next step for partial responders who want to maximize results.

When tirzepatide is not the automatic upgrade

Tirzepatide produces more weight loss on average, but "more" is not always "better" for every patient.

Situations where semaglutide may be the better choice:

1. Patients with established cardiovascular disease. Semaglutide has proven CV benefit in the SELECT trial. Tirzepatide's CV outcomes trial is ongoing. If you have a history of heart attack, stroke, or peripheral artery disease, the known benefit outweighs the incremental weight-loss advantage until tirzepatide's CV data is published.

2. Patients who have reached goal weight on semaglutide. If you have lost 15% of body weight, maintained it for 6+ months, and feel satisfied with your results, there is no medical reason to switch. The additional 3% to 5% tirzepatide might offer is not worth the cost and re-titration process.

3. Patients with a history of pancreatitis. Both medications carry a pancreatitis warning, but tirzepatide's dual mechanism may pose a higher theoretical risk. The data is not conclusive, but conservative clinicians often prefer semaglutide in patients with prior pancreatitis.

4. Patients who cannot tolerate weekly injections above 1 mg. Some patients experience injection site reactions, bruising, or anxiety around injections. Semaglutide allows effective treatment at 1 mg weekly. Tirzepatide's effective doses start at 5 mg, which is a larger injection volume.

5. Patients prioritizing speed to maintenance dose. Semaglutide reaches maintenance at 12 weeks. Tirzepatide takes 20 weeks. For patients who want results quickly and are willing to accept slightly less total weight loss, semaglutide is the faster path.

The broader point: "dual agonist" does not mean "better for everyone." The decision requires matching mechanism to patient goals, tolerance, and clinical context.

FAQ

What is the main difference between Ozempic and tirzepatide? Ozempic contains semaglutide, which activates only GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP receptors. The dual mechanism produces greater weight loss (average 15% to 21% vs 10% to 15%) and slightly better A1C reduction in diabetes patients.

Is tirzepatide stronger than Ozempic? Tirzepatide produces more weight loss than semaglutide (Ozempic's active ingredient) at comparable doses. In head-to-head trials, tirzepatide 15 mg caused 15.7% weight loss vs 8.2% for semaglutide 1 mg over 72 weeks. "Stronger" depends on whether you measure by weight loss, A1C reduction, or side effect intensity.

Can I switch from Ozempic to tirzepatide? Yes. Patients commonly switch from semaglutide to tirzepatide, especially if weight loss plateaus. Most providers recommend starting tirzepatide at 2.5 mg weekly regardless of your semaglutide dose, then titrating up every 4 weeks. No washout period is required.

Which has worse side effects, Ozempic or tirzepatide? Semaglutide 2.4 mg (Wegovy dose) has higher nausea rates (44%) than tirzepatide 15 mg (33%) in clinical trials. At lower doses, side effect rates are similar. Both cause nausea, vomiting, diarrhea, and constipation through the same gastric-slowing mechanism.

Is tirzepatide better for weight loss than Ozempic? Yes, on average. Tirzepatide produces 5% to 6% more total body weight loss than semaglutide at maximum doses. Tirzepatide 15 mg averages 20.9% weight loss vs 14.9% for semaglutide 2.4 mg in obesity trials. Individual results vary.

Does tirzepatide lower A1C more than Ozempic? Slightly. Tirzepatide 15 mg reduced A1C by 2.30% vs 1.86% for semaglutide 1 mg in the SURPASS-2 trial. The difference is clinically meaningful but smaller than the weight-loss difference. Both medications effectively control blood sugar in type 2 diabetes.

Why does tirzepatide cost more than Ozempic? Retail list prices are similar (around $1,000 to $1,350 per month), but insurance coverage differs. Ozempic is widely covered for diabetes. Tirzepatide's obesity formulation (Zepbound) is often not covered. For patients paying out of pocket, compounded versions of both cost $250 to $450 monthly.

Can I take Ozempic and tirzepatide together? No. Both medications activate GLP-1 receptors. Taking them together would not increase effectiveness and would significantly increase side effects and hypoglycemia risk. Patients should use one or the other, not both.

Which is better for diabetes, Ozempic or tirzepatide? Tirzepatide (Mounjaro) produces slightly better A1C reduction and more patients reach A1C below 7.0% (93% vs 82% in SURPASS-2). Both are effective. The choice depends on insurance coverage, cost, and whether weight loss is also a goal.

How long does it take to see results on tirzepatide vs Ozempic? Both show weight loss within 4 to 8 weeks. Tirzepatide produces faster initial weight loss but takes longer to reach maintenance dose (20 weeks vs 12 weeks). By 6 months, tirzepatide typically shows greater total weight loss.

Is compounded tirzepatide the same as Mounjaro or Zepbound? Compounded tirzepatide contains the same active ingredient but is not FDA-approved and is not manufactured by Eli Lilly. Compounded versions are prepared by state-licensed pharmacies and have not undergone the same testing as brand-name products. They are not interchangeable.

Does tirzepatide work faster than Ozempic? Tirzepatide's starting dose (2.5 mg) delivers more GLP-1 activation than semaglutide's starting dose (0.25 mg), so some patients see faster initial weight loss. However, semaglutide reaches maintenance dose in 12 weeks vs 20 weeks for tirzepatide, so "faster" depends on how you measure.

Sources

1. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Science Translational Medicine. 2021.
2. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Nature Medicine. 2023.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
5. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. New England Journal of Medicine. 2021.
6. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023.
7. Urva S et al. Comparison of gastrointestinal tolerability of tirzepatide versus semaglutide in patients with type 2 diabetes: post hoc analysis of the SURPASS-2 trial. Diabetes, Obesity and Metabolism. 2023.
8. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): gastric emptying substudy. Diabetes Care. 2023.
9. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
10. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
11. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
12. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.
13. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
14. FDA Drug Shortages Database. Semaglutide and tirzepatide injection shortage status. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company, respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.